Suppressor of cytokine signaling and accelerated atherosclerosis in kidney disease

• Autorzy: Wesoly J. , Sikorski K. , Lee C.-K. , Bluyssen A. R.
• Języki publikacji: EN

Abstrakty

EN

The prevalence of cardiovascular disease in patients with renal failure is extremely high and accounts for a large part of the morbidity and mortality. Inflammation participates importantly in host defense against infectious agents and injury, but also contributes to the pathophysiology of many diseases, including cardiovascular atherosclerosis, which is a main problem in patients with renal failure. Recruitment of blood leukocytes to the injured vascular endothelium characterizes the initiation and progression of atherosclerosis and involves many inflammatory mediators, modulated by cells of both innate and adaptive immunity. Excessive inflammatory and immune responses, communicated by these different cell types, are driven by inflammatory cytokines that promote associated tissue damage if cytokine signaling pathways remain unregulated. Thus, pathways capable of suppressing proinflammatory cytokine signaling hold the potential to limit life-threatening cardiovascular events caused by atherogenesis. Suppressor of cytokine signaling (SOCS) are a family of intracellular proteins, several of which have emerged as key physiological regulators of cytokine-mediated homeostasis, including innate and adaptive immunity. Accumulating evidence supports the idea that dysregulation of cytokine signaling by differential SOCS expression is involved in the pathogenesis of various inflammatory, and immunological diseases, including atherosclerosis. Based on recent observations, in which SOCS expression levels are profoundly altered in kidney disease, we discuss the possibilities of SOCS as new intracellular markers of inflammation as well as their potential atherogenic properties in renal failure related cardiovascular disease.

Słowa kluczowe

EN

cytokine signalling; atherosclerosis; human disease; kidney disease; cardiovascular disease; inflammation; chronic renal failure

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2010
• Tom: 57
• Numer: 3
• Opis fizyczny: p.251-260,fig.,ref.

Twórcy

autor

Wesoly J.

• Laboratory of Human Molecular Genetics, Institute of Molecular Biology and Biotechnology, Faculty of Biology, University of Adam Mickiewicz, Poznan, Poland

autor

Sikorski K.

autor

Lee C.-K.

autor

Bluyssen A. R.

Bibliografia

• Alexander WS, Hilton DJ (2004) The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol 22: 503-529. 
• Alexander WS, Starr R, Fenner JE, Scott CL, Handman E, Sprigg NS, Corbin JE, Cornish AL, Darwiche R, Owczarek CM, Kay TW, Nicola NA, Hertzog PJ, Metcalf D, Hilton DJ (1999a) SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 98: 597-608. 
• Alexander WS, Starr R, Metcalf D, Nicholson SE, Farley A, Elefanty AG, Brysha M, Kile BT, Richardson R, Baca M, Zhang JG, Willson TA, Viney EM, Sprigg NS, Rakar S, Corbin J, Mifsud S, DiRago L, Cary D, Nicola NA, Hilton DJ (1999b) Suppressors of cytokine signaling (SOCS): negative regulators of signal transduction. J Leukoc Biol 66: 588-592. 
• Annuk M, Lind L, Linde T, Fellstrom B (2001) Impaired endothelium-dependent vasodilatation in renal failure in humans. Nephrol Dial Transplant 16: 302-306. 
• Auernhammer CJ, Melmed S (2001) The central role of SOCS-3 in integrating the neuro-immunoendocrine interface. J Clin Invest 108: 1735-1740. 
• Banerjee A, Banks AS, Nawijn MC, Chen XP, Rothman PB (2002) Cutting edge: suppressor of cytokine signaling 3 inhibits activation of NFATp. J Immunol 168: 4277-4281. 
• Banks AS, Li J, McKeag L, Hribal ML, Kashiwada M, Accili D, Rothman PB (2005) Deletion of SOCS7 leads to enhanced insulin action and enlarged islets of Langerhans. J Clin Invest 115: 2462-2471. 
• Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM (1999) Impact of aortic stiffness on survival in end-stage renal disease. Circulation 99: 2434-2439. 
• Bluyssen HA, Rastmanesh MM, Tilburgs C, Jie KE, Wesseling S, Goumans MJ, Boer P, Joles JA, Braam B (2010) IFNγ-dependent SOCS3 expression inhibits IL-6 induced STAT3 phosphorylation and differentially affects IL-6 mediated transcriptional responses in endothelial cells. Am J Physiol Cell Physiol 299: C354-C362. 
• Bolton CH, Downs LG, Victory JG, Dwight JF, Tomson CR, Mackness MI, Pinkney JH (2001) Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant 16: 1189-1197. 
• Brauner A, Lu Y, Hallden G, Hylander B, Lundahl J (1998) Difference in the blood monocyte phenotype between uremic patients and healthy controls: its relation to monocyte differentiation into macrophages in the peritoneal cavity. Inflammation 22: 55-66. 
• Brender C, Columbus R, Metcalf D, Handman E, Starr R, Huntington N, Tarlinton D, Odum N, Nicholson SE, Nicola NA, Hilton DJ, Alexander WS (2004) SOCS5 is expressed in primary B and T lymphoid cells but is dispensable for lymphocyte production and function. Mol Cell Biol 24: 6094-6103. 
• Briet M, Bozec E, Laurent S, Fassot C, London GM, Jacquot C, Froissart M, Houillier P, Boutouyrie P (2006) Arterial stiffness and enlargement in mild-to-moderate chronic kidney disease. Kidney Int 69: 350-357. 
• Chan CM (2005) Hyperlipidaemia in chronic kidney disease. Ann Acad Med Singapore 34: 31-35. 
• Chen Y, Chong MM, Darwiche R, Thomas HE, Kay TW (2004) Severe pancreatitis with exocrine destruction and increased islet neogenesis in mice with suppressor of cytokine signaling-1 deficiency. Am J Pathol 165: 913-921. 
• Chesnokova V, Melmed S (2002) Minireview: Neuro-immuno-endocrine modulation of the hypothalamic-pituitary-adrenal (HPA) axis by gp130 signaling molecules. Endocrinology 143: 1571-1574. 
• Collins AJ, Li S, Gilbertson DT, Liu J, Chen SC, Herzog CA (2003) Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int Suppl (87): S24-31. 
• Croker BA, Krebs DL, Zhang JG, Wormald S, Willson TA, Stanley EG, Robb L, Greenhalgh CJ, Forster I, Clausen BE, Nicola NA, Metcalf D, Hilton DJ, Roberts AW, Alexander WS (2003) SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 4: 540-545. 
• Croker BA, Metcalf D, Robb L, Wei W, Mifsud S, DiRago L, Cluse LA, Sutherland KD, Hartley L, Williams E, Zhang JG, Hilton DJ, Nicola NA, Alexander WS, Roberts AW (2004) SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis. Immunity 20: 153-165. 
• Dalpke A, Heeg K, Bartz H, Baetz A (2008) Regulation of innate immunity by suppressor of cytokine signaling (SOCS) proteins. Immunobiology 213: 225-235. 
• Dhondt A, Vanholder R, Van Biesen W, Lameire N (2000) The removal of uremic toxins. Kidney Int Suppl 76: S47-59. 
• Dinarello CA (1997) Role of pro- and anti-inflammatory cytokines during inflammation: experimental and clinical findings. J Biol Regul Homeost Agents 11: 91-103. 
• Egan PJ, Lawlor KE, Alexander WS, Wicks IP (2003) Suppressor of cytokine signaling-1 regulates acute inflammatory arthritis and T cell activation. J Clin Invest 111: 915-924. 
• Egwuagu CE, Yu CR, Zhang M, Mahdi RM, Kim SJ, Gery I (2002) Suppressors of cytokine signaling proteins are differentially expressed in Th1 and Th2 cells: implications for Th cell lineage commitment and maintenance. J Immunol 168: 3181-3187. 
• Fujimoto M, Tsutsui H, Xinshou O, Tokumoto M, Watanabe D, Shima Y, Yoshimoto T, Hirakata H, Kawase I, Nakanishi K, Kishimoto T, Naka T (2004) Inadequate induction of suppressor of cytokine signaling-1 causes systemic autoimmune diseases. Int Immunol 16: 303-314. 
• Galle J, Quaschning T, Seibold S, Wanner C (2003) Endothelial dysfunction and inflammation: what is the link? Kidney Int Suppl (84): S45-49. 
• Gomez-Guerrero C, Lopez-Franco O, Sanjuan G, Hernandez-Vargas P, Suzuki Y, Ortiz-Munoz G, Blanco J, Egido J (2004) Suppressors of cytokine signaling regulate Fc receptor signaling and cell activation during immune renal injury. J Immunol 172: 6969-6977. 
• Greenhalgh CJ, Metcalf D, Thaus AL, Corbin JE, Uren R, Morgan PO, Fabri LJ, Zhang JG, Martin HM, Willson TA, Billestrup N, Nicola NA, Baca M, Alexander WS, Hilton DJ (2002) Biological evidence that SOCS-2 can act either as an enhancer or suppressor of growth hormone signaling. J Biol Chem 277: 40181-40184. 
• Greenhalgh CJ, Rico-Bautista E, Lorentzon M, Thaus AL, Morgan PO, Willson TA, Zervoudakis P, Metcalf D, Street I, Nicola NA, Nash AD, Fabri LJ, Norstedt G, Ohlsson C, Flores-Morales A, Alexander WS, Hilton DJ (2005) SOCS2 negatively regulates growth hormone action in vitro and in vivo. J Clin Invest 115: 397-406. 
• Grimble RF (2002) Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab Care 5: 551-559. 
• Hack CE, Zeerleder S (2001) The endothelium in sepsis: source of and a target for inflammation. Crit Care Med 29: S21-S27. 
• Hansson GK, Robertson AK, Soderberg-Naucler C (2006) Inflammation and atherosclerosis. Annu Rev Pathol 1: 297-329. 
• Heine GH, Ulrich C, Seibert E, Seiler S, Marell J, Reichart B, Krause M, Schlitt A, Kohler H, Girndt M (2008) CD14(++)CD16+monocytes but not total monocyte numbers predict cardiovascular events in dialysis patients. Kidney Int 73: 622-629. 
• Hernandez-Vargas P, Lopez-Franco O, Sanjuan G, Ruperez M, Ortiz-Munoz G, Suzuki Y, Aguado-Roncero P, Perez-Tejerizo G, Blanco J, Egido J, Ruiz-Ortega M, Gomez-Guerrero C (2005) Suppressors of cytokine signaling regulate angiotensin II-activated Janus kinase-signal transducers and activators of transcription pathway in renal cells. J Am Soc Nephrol 16: 1673-1683. 
• Himmelfarb J, McMonagle E, McMenamin E (2000) Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney Int 58: 2571-2578. 
• Kamura T, Sato S, Haque D, Liu L, Kaelin WG Jr, Conaway RC, Conaway JW (1998) The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev 12: 3872-3881. 
• Kario E, Marmor MD, Adamsky K, Citri A, Amit I, Amariglio N, Rechavi G, Yarden Y (2005) Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor receptor signaling. J Biol Chem 280: 7038-7048. 
• Kato A, Odamaki M, Takita T, Maruyama Y, Kumagai H, Hishida A (2002) Association between interleukin-6 and carotid atherosclerosis in hemodialysis patients. Kidney Int 61: 1143-1152. 
• Kimura A, Kinjyo I, Matsumura Y, Mori H, Mashima R, Harada M, Chien KR, Yasukawa H, Yoshimura A (2004) SOCS3 is a physiological negative regulator for granulopoiesis and granulocyte colony-stimulating factor receptor signaling. J Biol Chem 279: 6905-6910. 
• Krebs DL, Hilton DJ (2001) SOCS proteins: negative regulators of cytokine signaling. Stem Cells 19: 378-387. 
• Krebs DL, Uren RT, Metcalf D, Rakar S, Zhang JG, Starr R, De Souza DP, Hanzinikolas K, Eyles J, Connolly LM, Simpson RJ, Nicola NA, Nicholson SE, Baca M, Hilton DJ, Alexander WS (2002) SOCS-6 binds to insulin receptor substrate 4, and mice lacking the SOCS-6 gene exhibit mild growth retardation. Mol Cell Biol 22: 4567-4578. 
• Krebs DL, Metcalf D, Merson TD, Voss AK, Thomas T, Zhang JG, Rakar S, O'Bryan MK, Willson TA, Viney EM, Mielke LA, Nicola NA, Hilton DJ, Alexander WS (2004) Development of hydrocephalus in mice lacking SOCS7. Proc Natl Acad Sci USA 101: 15446-15451. 
• Kwak BR, Mulhaupt F, Mach F (2003) Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins. Autoimmun Rev 2: 332-338. 
• Lang R, Pauleau AL, Parganas E, Takahashi Y, Mages J, Ihle JN, Rutschman R, Murray PJ (2003) SOCS3 regulates the plasticity of gp130 signaling. Nat Immunol 4: 546-550. 
• Leon ML, Zuckerman SH (2005) Gamma interferon: a central mediator in atherosclerosis. Inflamm Res 54: 395-411. 
• Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA, Wenger NK, Wilson PW, Wright JT Jr (1998) Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 32: 853-906. 
• Levy DE, Darnell JE Jr (2002) Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3: 651-662. 
• Levy DE, Lee CK (2002) What does Stat3 do? J Clin Invest 109: 1143-1148. 
• Li S, Chen S, Xu X, Sundstedt A, Paulsson KM, Anderson P, Karlsson S, Sjogren HO, Wang P (2000) Cytokine-induced Src homology 2 protein (CIS) promotes T cell receptor-mediated proliferation and prolongs survival of activated T cells. J Exp Med 191: 985-994. 
• Libby P (2002) Inflammation in atherosclerosis. Nature 420: 868-874. 
• Lin JJ, Tonshoff B, Bouriquet N, Casellas D, Kaskel FJ, Moore LC (1998) Insulin-like growth factor-I restores microvascular autoregulation in experimental chronic renal failure. Kidney Int Suppl 67: S195-S198. 
• Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C (2003) Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 18: 1272-1280. 
• Losman JA, Chen XP, Hilton D, Rothman P (1999) Cutting edge: SOCS-1 is a potent inhibitor of IL-4 signal transduction. J Immunol 162: 3770-3774. 
• Mansell A, Smith R, Doyle SL, Gray P, Fenner JE, Crack PJ, Nicholson SE, Hilton DJ, O'Neill LA, Hertzog PJ (2006) Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat Immunol 7: 148-155. 
• Marine JC, McKay C, Wang D, Topham DJ, Parganas E, Nakajima H, Pendeville H, Yasukawa H, Sasaki A, Yoshimura A, Ihle JN (1999) SOCS3 is essential in the regulation of fetal liver erythropoiesis. Cell 98: 617-627. 
• Mark AL, Correia ML, Rahmouni K, Haynes WG (2002) Selective leptin resistance: a new concept in leptin physiology with cardiovascular implications. J Hypertens 20: 1245-1250. 
• Martens N, Uzan G, Wery M, Hooghe R, Hooghe-Peters EL, Gertler A (2005) Suppressor of cytokine signaling 7 inhibits prolactin, growth hormone, and leptin signaling by interacting with STAT5 or STAT3 and attenuating their nuclear translocation. J Biol Chem 280: 13817-13823. 
• Martin-Malo A, Carracedo J, Ramirez R, Rodriguez-Benot A, Soriano S, Rodriguez M, Aljama P (2000) Effect of uremia and dialysis modality on mononuclear cell apoptosis. J Am Soc Nephrol 11: 936-942. 
• Mathur S, Devaraj S, Jialal I (2002) Accelerated atherosclerosis, dyslipidemia, and oxidative stress in end-stage renal disease. Curr Opin Nephrol Hypertens 11: 141-147. 
• Matsumoto A, Seki Y, Kubo M, Ohtsuka S, Suzuki A, Hayashi I, Tsuji K, Nakahata T, Okabe M, Yamada S, Yoshimura A (1999) Suppression of STAT5 functions in liver, mammary glands, and T cells in cytokine-inducible SH2-containing protein 1 transgenic mice. Mol Cell Biol 19: 6396-6407. 
• Menegatti E, Rossi D, Chiara M, Alpa M, Sena LM, Roccatello D (2002) Cytokine release pathway in mononuclear cells stimulated in vitro by dialysis membranes. Am J Nephrol 22: 509-514. 
• Miyazaki H, Matsuoka H, Itabe H, Usui M, Ueda S, Okuda S, Imaizumi T (2000) Hemodialysis impairs endothelial function via oxidative stress: effects of vitamin E-coated dialyzer. Circulation 101: 1002-1006. 
• Mori H, Hanada R, Hanada T, Aki D, Mashima R, Nishinakamura H, Torisu T, Chien KR, Yasukawa H, Yoshimura A (2004) Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity. Nat Med 10: 739-743. 
• Naka T, Matsumoto T, Narazaki M, Fujimoto M, Morita Y, Ohsawa Y, Saito H, Nagasawa T, Uchiyama Y, Kishimoto T (1998) Accelerated apoptosis of lymphocytes by augmented induction of Bax in SSI-1 (STAT-induced STAT inhibitor-1) deficient mice. Proc Natl Acad Sci USA 95: 15577-15582. 
• Nakagawa R, Naka T, Tsutsui H, Fujimoto M, Kimura A, Abe T, Seki E, Sato S, Takeuchi O, Takeda K, Akira S, Yamanishi K, Kawase I, Nakanishi K, Kishimoto T (2002) SOCS-1 participates in negative regulation of LPS responses. Immunity 17: 677-687. 
• Nicholson SE, De Souza D, Fabri LJ, Corbin J, Willson TA, Zhang JG, Silva A, Asimakis M, Farley A, Nash AD, Metcalf D, Hilton DJ, Nicola NA, Baca M (2000) Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc Natl Acad Sci USA 97: 6493-6498. 
• Niemand C, Nimmesgern A, Haan S, Fischer P, Schaper F, Rossaint R, Heinrich PC, Muller-Newen G (2003) Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3. J Immunol 170: 3263-3272. 
• Novak U, Marks D, Nicholson SE, Hilton D, Paradiso L (1999) Differential ability of SOCS proteins to regulate IL-6 and CSF-1 induced macrophage differentiation. Growth Factors 16: 305-314. 
• Ortiz-Munoz G, Martin-Ventura JL, Hernandez-Vargas P, Mallavia B, Lopez-Parra V, Lopez-Franco O, Munoz-Garcia B, Fernandez-Vizarra P, Ortega L, Egido J, Gomez-Guerrero C (2009) Suppressors of cytokine signaling modulate JAK/STAT-mediated cell responses during atherosclerosis. Arterioscler Thromb Vasc Biol 29: 525-531. 
• Raj DS, Dominic EA, Pai A, Osman F, Morgan M, Pickett G, Shah VO, Ferrando A, Moseley P (2005) Skeletal muscle, cytokines, and oxidative stress in end-stage renal disease. Kidney Int 68: 2338-2344. 
• Rastmanesh MM, Bluyssen HA, Joles JA, Boer P, Willekes N, Braam B (2008) Increased expression of SOCS3 in monocytes and SOCS1 in lymphocytes correlates with progressive loss of renal function and cardiovascular risk factors in chronic kidney disease. Eur J Pharmacol 593: 99-104. 
• Rastmanesh MM, Braam B, Joles JA, Boer P, Bluyssen HA (2009) Increased SOCS expression in peripheral blood mononuclear cells of end stage renal disease patients is related to inflammation and dialysis modality. Eur J Pharmacol 602: 163-167. 
• Roberts MA, Hare DL, Ratnaike S, Ierino FL (2006) Cardiovascular biomarkers in CKD: pathophysiology and implications for clinical management of cardiac disease. Am J Kidney Dis 48: 341-360. 
• Robertson AK, Hansson GK (2006) T cells in atherogenesis: for better or for worse? Arterioscler Thromb Vasc Biol 26: 2421-2432. 
• Roelfsema V, Clark RG (2001) The growth hormone and insulin-like growth factor axis: its manipulation for the benefit of growth disorders in renal failure. J Am Soc Nephrol 12: 1297-1306. 
• Roob JM, Khoschsorur G, Tiran A, Horina JH, Holzer H, Winklhofer-Roob BM (2000) Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 11: 539-549. 
• Rui L, Yuan M, Frantz D, Shoelson S, White MF (2002) SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 277: 42394-42398. 
• Saadeddin SM, Habbab MA, Ferns GA (2002) Markers of inflammation and coronary artery disease. Med Sci Monit 8: RA5-RA12. 
• Sasaki A, Yasukawa H, Shouda T, Kitamura T, Dikic I, Yoshimura A (2000) CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J Biol Chem 275: 29338-29347. 
• Schaefer F, Chen Y, Tsao T, Nouri P, Rabkin R (2001) Impaired JAK-STAT signal transduction contributes to growth hormone resistance in chronic uremia. J Clin Invest 108: 467-475. 
• Schnackenberg CG (2002) Oxygen radicals in cardiovascular-renal disease. Curr Opin Pharmacol 2: 121-125. 
• Seki Y, Hayashi K, Matsumoto A, Seki N, Tsukada J, Ransom J, Naka T, Kishimoto T, Yoshimura A, Kubo M (2002) Expression of the suppressor of cytokine signaling-5 (SOCS5) negatively regulates IL-4-dependent STAT6 activation and Th2 differentiation. Proc Natl Acad Sci USA 99: 13003-13008. 
• Sester U, Sester M, Hauk M, Kaul H, Kohler H, Girndt M (2000) T-cell activation follows Th1 rather than Th2 pattern in haemodialysis patients. Nephrol Dial Transplant 15: 1217-1223. 
• Shouda T, Yoshida T, Hanada T, Wakioka T, Oishi M, Miyoshi K, Komiya S, Kosai K, Hanakawa Y, Hashimoto K, Nagata K, Yoshimura A (2001) Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J Clin Invest 108: 1781-1788. 
• Starr R, Metcalf D, Elefanty AG, Brysha M, Willson TA, Nicola NA, Hilton DJ, Alexander WS (1998) Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1. Proc Natl Acad Sci USA 95: 14395-14399. 
• Stenvinkel P (2002) Inflammation in end-stage renal failure: could it be treated? Nephrol Dial Transplant 17 (Suppl 8): 33-38; discussion p 40. 
• Stenvinkel P, Barany P (2002) Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure; links to inflammation and oxidative stress. Nephrol Dial Transplant 17 (Suppl 5): 32-37. 
• Stenvinkel P, Pecoits-Filho R, Lindholm B (2003) Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol 14: 1927-1939. 
• Suzuki A, Hanada T, Mitsuyama K, Yoshida T, Kamizono S, Hoshino T, Kubo M, Yamashita A, Okabe M, Takeda K, Akira S, Matsumoto S, Toyonaga A, Sata M, Yoshimura A (2001) CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med 193: 471-481. 
• Takahashi Y, Carpino N, Cross JC, Torres M, Parganas E, Ihle JN (2003) SOCS3: an essential regulator of LIF receptor signaling in trophoblast giant cell differentiation. Embo J 22: 372-384. 
• Taleb S, Romain M, Ramkhelawon B, Uyttenhove C, Pasterkamp G, Herbin O, Esposito B, Perez N, Yasukawa H, Van Snick J, Yoshimura A, Tedgui A, Mallat Z (2009) Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med 206: 2067-2077. 
• Tang J, Raines EW (2005) Are suppressors of cytokine signaling proteins recently identified in atherosclerosis possible therapeutic targets? Trends Cardiovasc Med 15: 243-249. 
• Tang J, Kozaki K, Farr AG, Martin PJ, Lindahl P, Betsholtz C, Raines EW (2005) The absence of platelet-derived growth factor-B in circulating cells promotes immune and inflammatory responses in atherosclerosis-prone ApoE-/- mice. Am J Pathol 167: 901-912. 
• Tsirpanlis G (2007) Is inflammation the link between atherosclerosis and vascular calcification in chronic kidney disease? Blood Purif 25: 179-182. 
• van Guldener C, Janssen MJ, Lambert J, Steyn M, Donker AJ, Stehouwer CD (1998) Endothelium-dependent vasodilatation is impaired in peritoneal dialysis patients. Nephrol Dial Transplant 13: 1782-1786. 
• van Guldener C, Stam F, Stehouwer CD (2001) Homocysteine metabolism in renal failure. Kidney Int Suppl 78: S234-237. 
• Wang P, Li N, Li JS, Li WQ (2002) The role of endotoxin, TNF-alpha, and IL-6 in inducing the state of growth hormone insensitivity. World J Gastroenterol 8: 531-536. 
• Wanner C, Zimmermann J, Schwedler S, Metzger T (2002) Inflammation and cardiovascular risk in dialysis patients. Kidney Int Suppl 99-102. 
• Wesemann DR, Dong Y, O'Keefe GM, Nguyen VT, Benveniste EN (2002) Suppressor of cytokine signaling 1 inhibits cytokine induction of CD40 expression in macrophages. J Immunol 169: 2354-2360. 
• Wesoly J, Szweykowska-Kulinska Z, Bluyssen HA (2007) STAT activation and differential complex formation dictate selectivity of interferon responses. Acta Biochim Pol 54: 27-38. 
• Wheatcroft SB, Williams IL, Shah AM, Kearney MT (2003) Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet Med 20: 255-268. 
• Yamamoto TYH, Koga M, et al. (2007) Lacking the SOCS3 Gene in Macrophages Prevents the Development of Atherosclerosis in ApoE Deficient Mice. Circ J 71: 170.
• Yasukawa H, Misawa H, Sakamoto H, Masuhara M, Sasaki A, Wakioka T, Ohtsuka S, Imaizumi T, Matsuda T, Ihle JN, Yoshimura A (1999) The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. Embo J 18: 1309-1320. 
• Yasukawa H, Ohishi M, Mori H, Murakami M, Chinen T, Aki D, Hanada T, Takeda K, Akira S, Hoshijima M, Hirano T, Chien KR, Yoshimura A (2003) IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol 4: 551-556. 
• Yoshimura A, Ohkubo T, Kiguchi T, Jenkins NA, Gilbert DJ, Copeland NG, Hara T, Miyajima A (1995) A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. Embo J 14: 2816-2826. 
• Yoshimura A, Naka T, Kubo M (2007) SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 7: 454-465. 
• Zhang JG, Metcalf D, Rakar S, Asimakis M, Greenhalgh CJ, Willson TA, Starr R, Nicholson SE, Carter W, Alexander WS, Hilton DJ, Nicola NA (2001) The SOCS box of suppressor of cytokine signaling-1 is important for inhibition of cytokine action in vivo. Proc Natl Acad Sci USA 98: 13261-13265